S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:SLDB

Solid Biosciences (SLDB) Stock Price, News & Analysis

$13.32
-0.93 (-6.53%)
(As of 03/28/2024 ET)
Today's Range
$12.89
$15.05
50-Day Range
$6.77
$14.75
52-Week Range
$1.81
$15.05
Volume
871,448 shs
Average Volume
335,019 shs
Market Capitalization
$502.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.25

Solid Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
37.0% Upside
$18.25 Price Target
Short Interest
Healthy
2.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of Solid Biosciences in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$18.86 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.52) to ($2.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.36 out of 5 stars

Medical Sector

148th out of 939 stocks

Biological Products, Except Diagnostic Industry

20th out of 158 stocks

SLDB stock logo

About Solid Biosciences Stock (NASDAQ:SLDB)

Solid Biosciences Inc., a life science company, engages in developing therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne); AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia; AVB-401, a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and other drugs for the treatment of undisclosed cardiac diseases. It also engages in developing platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

SLDB Stock Price History

SLDB Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
SLDB Apr 2024 7.500 put
Solid Biosciences (SLDB) Gets a Buy from Barclays
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
SLDB Sep 2024 17.500 call
Solid Biosciences Stock Drops 4% Due To Wider Loss In Q4
Leerink Partners Keeps Their Hold Rating on Solid Biosciences (SLDB)
SLDB Mar 2024 10.000 put
Solid Biosciences LLC (SLDB)
Solid Biosciences Granted FDA ODD For SGT-003
See More Headlines
Receive SLDB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2024
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SLDB
Fax
N/A
Employees
88
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.25
High Stock Price Target
$21.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+37.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-96,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$8.09 million
Book Value
$6.27 per share

Miscellaneous

Free Float
30,459,000
Market Cap
$502.96 million
Optionable
Optionable
Beta
1.88
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Ian F. Smith A.C.A. (Age 58)
    C.P.A., Executive Chair
    Comp: $75k
  • Mr. Alexander G. Cumbo (Age 53)
    President, CEO & Director
    Comp: $1.82M
  • Mr. Ilan Ganot (Age 50)
    Co-founder, Strategic Advisor to the CEO & Director
    Comp: $1.36M
  • Mr. David Tyronne Howton Jr. (Age 52)
    J.D., COO & Secretary
    Comp: $1.4M
  • Mr. Gilad David Hayeem (Age 56)
    Co-Founder
  • Ms. Annie Ganot
    Co-Founder & Head of Patient Advocacy
  • Dr. Andrey Juan Zarur Ph.D. (Age 53)
    Co-Founder
    Comp: $90.17k
  • Mr. Kevin Tan C.F.A. (Age 47)
    CFO & Treasurer
  • Mr. Stephen J. Di Palma M.B.A. (Age 65)
    Treasurer & Principal Accounting Officer
  • Mr. Paul Herzich (Age 46)
    Chief Technology Officer

SLDB Stock Analysis - Frequently Asked Questions

Should I buy or sell Solid Biosciences stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLDB shares.
View SLDB analyst ratings
or view top-rated stocks.

What is Solid Biosciences' stock price target for 2024?

6 Wall Street research analysts have issued 1-year price objectives for Solid Biosciences' stock. Their SLDB share price targets range from $16.00 to $21.00. On average, they anticipate the company's stock price to reach $18.25 in the next year. This suggests a possible upside of 37.0% from the stock's current price.
View analysts price targets for SLDB
or view top-rated stocks among Wall Street analysts.

How have SLDB shares performed in 2024?

Solid Biosciences' stock was trading at $6.14 at the beginning of the year. Since then, SLDB shares have increased by 116.9% and is now trading at $13.32.
View the best growth stocks for 2024 here
.

When is Solid Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SLDB earnings forecast
.

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc. (NASDAQ:SLDB) released its earnings results on Wednesday, March, 13th. The company reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.01) by $0.01.

When did Solid Biosciences' stock split?

Solid Biosciences's stock reverse split on Friday, October 28th 2022. The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Solid Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Selecta Biosciences (SELB), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Cidara Therapeutics (CDTX), SCYNEXIS (SCYX), Verastem (VSTM) and Agile Therapeutics (AGRX).

When did Solid Biosciences IPO?

Solid Biosciences (SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.

Who are Solid Biosciences' major shareholders?

Solid Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.61%), Vanguard Group Inc. (1.61%), Bridgeway Capital Management LLC (0.25%), Dimensional Fund Advisors LP (0.25%), Vestal Point Capital LP (0.17%) and Northern Trust Corp (0.14%). Insiders that own company stock include Alexander Cumbo, Carl Ashley Morris, David T Howton, Ilan Ganot, Jessie Hanrahan, Joel Solomon Zev Schneider, Kevin Tan, Paul Herzich and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Solid Biosciences?

Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLDB) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners